Forest Laboratories

CompanyUnited States

Forest Laboratories develops one asset, approved (memantine in Alzheimer's disease). Mostly small molecule acting on GRIN2B, GRIN1 and GRIN2A; based in the United States.

Assets
1
Furthest
Approved
Trials
13
Signals
0

Pipeline

1

  • memantine

    Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity

    ApprovedSmall moleculeGRIN2BGRIN1Alzheimer's diseasedementia

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials40
  • Similar companies6

Updated 7 Oct 2026 · 74 sources

Intelligence